Report cover image

Global Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 191 Pages
SKU # APRC20561618

Description

Summary

According to APO Research, The global Phosphodiesterase (PDE) inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Phosphodiesterase (PDE) inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Phosphodiesterase (PDE) inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Phosphodiesterase (PDE) inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Phosphodiesterase (PDE) inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Phosphodiesterase (PDE) inhibitors include Eli Lilly and Co., Pfizer Inc., GlaxoSmithKline Plc, Bayer AG and Vivus Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Phosphodiesterase (PDE) inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Phosphodiesterase (PDE) inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Phosphodiesterase (PDE) inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Phosphodiesterase (PDE) inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Phosphodiesterase (PDE) inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Phosphodiesterase (PDE) inhibitors sales, projected growth trends, production technology, application and end-user industry.

Phosphodiesterase (PDE) inhibitors Segment by Company

Eli Lilly and Co.
Pfizer Inc.
GlaxoSmithKline Plc
Bayer AG
Vivus Inc.
Phosphodiesterase (PDE) inhibitors Segment by Type

PDE10 selective inhibitors
PDE1 Selective Inhibitors
PDE2 Selective Inhibitors
PDE3 Selective Inhibitors
PDE4 selective inhibitors
PDE5 selective inhibitors
PDE7 selective inhibitors
Phosphodiesterase (PDE) inhibitors Segment by Application

Oral
Topical
Other
Phosphodiesterase (PDE) inhibitors Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphodiesterase (PDE) inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Phosphodiesterase (PDE) inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphodiesterase (PDE) inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Phosphodiesterase (PDE) inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Phosphodiesterase (PDE) inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phosphodiesterase (PDE) inhibitors sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Phosphodiesterase (PDE) inhibitors Market by Type
1.2.1 Global Phosphodiesterase (PDE) inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PDE10 selective inhibitors
1.2.3 PDE1 Selective Inhibitors
1.2.4 PDE2 Selective Inhibitors
1.2.5 PDE3 Selective Inhibitors
1.2.6 PDE4 selective inhibitors
1.2.7 PDE5 selective inhibitors
1.2.8 PDE7 selective inhibitors
1.3 Phosphodiesterase (PDE) inhibitors Market by Application
1.3.1 Global Phosphodiesterase (PDE) inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Oral
1.3.3 Topical
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Phosphodiesterase (PDE) inhibitors Market Dynamics
2.1 Phosphodiesterase (PDE) inhibitors Industry Trends
2.2 Phosphodiesterase (PDE) inhibitors Industry Drivers
2.3 Phosphodiesterase (PDE) inhibitors Industry Opportunities and Challenges
2.4 Phosphodiesterase (PDE) inhibitors Industry Restraints
3 Global Market Growth Prospects
3.1 Global Phosphodiesterase (PDE) inhibitors Revenue Estimates and Forecasts (2020-2031)
3.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Region
3.2.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2020-2025)
3.2.3 Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2026-2031)
3.2.4 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Region (2020-2031)
3.3 Global Phosphodiesterase (PDE) inhibitors Sales Estimates and Forecasts 2020-2031
3.4 Global Phosphodiesterase (PDE) inhibitors Sales by Region
3.4.1 Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Phosphodiesterase (PDE) inhibitors Sales by Region (2020-2025)
3.4.3 Global Phosphodiesterase (PDE) inhibitors Sales by Region (2026-2031)
3.4.4 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Manufacturers
4.1.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Manufacturers (2020-2025)
4.1.2 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Phosphodiesterase (PDE) inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Phosphodiesterase (PDE) inhibitors Sales by Manufacturers
4.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Manufacturers (2020-2025)
4.2.2 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Phosphodiesterase (PDE) inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Phosphodiesterase (PDE) inhibitors Sales Price by Manufacturers (2020-2025)
4.4 Global Phosphodiesterase (PDE) inhibitors Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Phosphodiesterase (PDE) inhibitors Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Phosphodiesterase (PDE) inhibitors Manufacturers, Product Type & Application
4.7 Global Phosphodiesterase (PDE) inhibitors Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Phosphodiesterase (PDE) inhibitors Market CR5 and HHI
4.8.2 2024 Phosphodiesterase (PDE) inhibitors Tier 1, Tier 2, and Tier 3
5 Phosphodiesterase (PDE) inhibitors Market by Type
5.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Type
5.1.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2020-2031)
5.2 Global Phosphodiesterase (PDE) inhibitors Sales by Type
5.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031) & (L)
5.2.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2020-2031)
5.3 Global Phosphodiesterase (PDE) inhibitors Price by Type
6 Phosphodiesterase (PDE) inhibitors Market by Application
6.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Application
6.1.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2020-2031)
6.2 Global Phosphodiesterase (PDE) inhibitors Sales by Application
6.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031) & (L)
6.2.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2020-2031)
6.3 Global Phosphodiesterase (PDE) inhibitors Price by Application
7 Company Profiles
7.1 Eli Lilly and Co.
7.1.1 Eli Lilly and Co. Comapny Information
7.1.2 Eli Lilly and Co. Business Overview
7.1.3 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Product Portfolio
7.1.5 Eli Lilly and Co. Recent Developments
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Comapny Information
7.2.2 Pfizer Inc. Business Overview
7.2.3 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
7.2.5 Pfizer Inc. Recent Developments
7.3 GlaxoSmithKline Plc
7.3.1 GlaxoSmithKline Plc Comapny Information
7.3.2 GlaxoSmithKline Plc Business Overview
7.3.3 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Product Portfolio
7.3.5 GlaxoSmithKline Plc Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Comapny Information
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Phosphodiesterase (PDE) inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Bayer AG Phosphodiesterase (PDE) inhibitors Product Portfolio
7.4.5 Bayer AG Recent Developments
7.5 Vivus Inc.
7.5.1 Vivus Inc. Comapny Information
7.5.2 Vivus Inc. Business Overview
7.5.3 Vivus Inc. Phosphodiesterase (PDE) inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Vivus Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
7.5.5 Vivus Inc. Recent Developments
8 North America
8.1 North America Phosphodiesterase (PDE) inhibitors Market Size by Type
8.1.1 North America Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031)
8.1.2 North America Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031)
8.1.3 North America Phosphodiesterase (PDE) inhibitors Price by Type (2020-2031)
8.2 North America Phosphodiesterase (PDE) inhibitors Market Size by Application
8.2.1 North America Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031)
8.2.2 North America Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031)
8.2.3 North America Phosphodiesterase (PDE) inhibitors Price by Application (2020-2031)
8.3 North America Phosphodiesterase (PDE) inhibitors Market Size by Country
8.3.1 North America Phosphodiesterase (PDE) inhibitors Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Phosphodiesterase (PDE) inhibitors Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Phosphodiesterase (PDE) inhibitors Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Phosphodiesterase (PDE) inhibitors Market Size by Type
9.1.1 Europe Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031)
9.1.2 Europe Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031)
9.1.3 Europe Phosphodiesterase (PDE) inhibitors Price by Type (2020-2031)
9.2 Europe Phosphodiesterase (PDE) inhibitors Market Size by Application
9.2.1 Europe Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031)
9.2.2 Europe Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031)
9.2.3 Europe Phosphodiesterase (PDE) inhibitors Price by Application (2020-2031)
9.3 Europe Phosphodiesterase (PDE) inhibitors Market Size by Country
9.3.1 Europe Phosphodiesterase (PDE) inhibitors Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Phosphodiesterase (PDE) inhibitors Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Phosphodiesterase (PDE) inhibitors Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Phosphodiesterase (PDE) inhibitors Market Size by Type
10.1.1 China Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031)
10.1.2 China Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031)
10.1.3 China Phosphodiesterase (PDE) inhibitors Price by Type (2020-2031)
10.2 China Phosphodiesterase (PDE) inhibitors Market Size by Application
10.2.1 China Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031)
10.2.2 China Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031)
10.2.3 China Phosphodiesterase (PDE) inhibitors Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Phosphodiesterase (PDE) inhibitors Market Size by Type
11.1.1 Asia Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031)
11.1.2 Asia Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031)
11.1.3 Asia Phosphodiesterase (PDE) inhibitors Price by Type (2020-2031)
11.2 Asia Phosphodiesterase (PDE) inhibitors Market Size by Application
11.2.1 Asia Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031)
11.2.2 Asia Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031)
11.2.3 Asia Phosphodiesterase (PDE) inhibitors Price by Application (2020-2031)
11.3 Asia Phosphodiesterase (PDE) inhibitors Market Size by Country
11.3.1 Asia Phosphodiesterase (PDE) inhibitors Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Phosphodiesterase (PDE) inhibitors Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Phosphodiesterase (PDE) inhibitors Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Phosphodiesterase (PDE) inhibitors Market Size by Type
12.1.1 SAMEA Phosphodiesterase (PDE) inhibitors Revenue by Type (2020-2031)
12.1.2 SAMEA Phosphodiesterase (PDE) inhibitors Sales by Type (2020-2031)
12.1.3 SAMEA Phosphodiesterase (PDE) inhibitors Price by Type (2020-2031)
12.2 SAMEA Phosphodiesterase (PDE) inhibitors Market Size by Application
12.2.1 SAMEA Phosphodiesterase (PDE) inhibitors Revenue by Application (2020-2031)
12.2.2 SAMEA Phosphodiesterase (PDE) inhibitors Sales by Application (2020-2031)
12.2.3 SAMEA Phosphodiesterase (PDE) inhibitors Price by Application (2020-2031)
12.3 SAMEA Phosphodiesterase (PDE) inhibitors Market Size by Country
12.3.1 SAMEA Phosphodiesterase (PDE) inhibitors Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Phosphodiesterase (PDE) inhibitors Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Phosphodiesterase (PDE) inhibitors Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Phosphodiesterase (PDE) inhibitors Value Chain Analysis
13.1.1 Phosphodiesterase (PDE) inhibitors Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Phosphodiesterase (PDE) inhibitors Production Mode & Process
13.2 Phosphodiesterase (PDE) inhibitors Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Phosphodiesterase (PDE) inhibitors Distributors
13.2.3 Phosphodiesterase (PDE) inhibitors Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.